

INTEGRATING THE PREVENTION AGENDA FOR BRAIN AND BODY HEALTH

Maria Duggan, Rosemary Calder, Ben Harris




About us

The Mitchell Institute for Education and Health Policy at Victoria University is one of the country's leading education and health policy think tanks and trusted thought leaders. Our focus is on improving our education and health systems so more Australians can engage with and benefit from these services, supporting a healthier, fairer and more productive society.

The Australian Health Policy Collaboration is led by the Mitchell Institute at Victoria University and brings together leading health organisations and chronic disease experts to translate rigorous research into good policy. The national collaboration has developed health targets and indicators for preventable chronic diseases designed to contribute to reducing the health impacts of chronic conditions on the Australian population.

Process

The Mitchell Institute's policy evidence briefs are short monographs highlighting the key evidence for emerging policy issues. We work with our partners in the Australian Health Policy Collaboration to seek expert advice on topics, content and context.



Acknowledgements

The Mitchell Institute acknowledges the contribution of a range of experts for helpful advice and contributions to this policy evidence brief. A list of those who have contributed to the identification and analysis of the evidence can be found at Appendix 2.

This project has been partially funded by the Australian Government Department of Health.

Suggested citation

Duggan, M, Calder R & Harris, B. Integrating the prevention agenda for brain and body health. Mitchell Institute Policy evidence brief no.1-2019, Victoria University. Melbourne.

ISBN: 978-0-6482621-8-3

Purpose

This briefing has been prepared by the Mitchell Institute at Victoria University for the Australian Government.

The briefing summarises the main findings of the mounting scientific evidence regarding the shared risk factors for brain and body health and for prevention.

The briefing addresses some of the policy implications of these findings for consideration by policymakers, by administrators and professional and education and training organisations. It should be noted that these policy proposals are made as interim measures only. An extensive process of consulting on the implications of this evidence for health policy is currently underway with a broad range of expert individuals and bodies. This will inform the development of a more extensive policy framework for the prevention of cognitive decline and dementia, supported by a broad consensus of expert opinion.

The information set out here is extracted from a longer summary of the evidence, published as a technical paper by the Mitchell Institute in 2019.

Research and development strategy

The evidence summarised in this briefing was identified through a wide-ranging, though non-systematic, scholarly review of the published literature. A range of search terms were used to build a comprehensive evidence base. Wherever possible, efforts were made to identify high-impact factor research publications.

The policy implications emerged through a series of formal and informal conversations with both Australian and global experts in the fields of public health, chronic disease prevention and dementia and one well-attended round table discussion held in 2018.

The policy problem

Societal ageing is a challenge for Australia and most countries in the world. Most health systems are poorly prepared to respond to the needs presented, including increasing dementia prevalence. However, fatalism in the face of these circumstances is not an appropriate response. Dementia is not an inevitable consequence of ageing. There is good - and growing - evidence that it is possible to delay or prevent a significant proportion of this burden of disease and disability by tackling a number of known risk factors at individual and population levels. Several of these risk factors are common to chronic conditions of both the body and brain, especially cardiovascular disease. Yet there is poor public understanding of these risks and their impacts on both brain and body health.

Finland has taken a unique national strategic approach to the prevention of dementia and the promotion of brain health, which could provide an evidence-based model for similar initiatives in Australia. In 2013, the Finnish Ministry of Social Affairs and Health published its [national plan](#), *Creating a Memory-Friendly Finland*, which addresses both dementia and brain health.¹ However, apart from this notable example, dementia policies worldwide tend to emphasise social care and other service provision, clinical and management practices for people with dementia, support for carers and ‘information’, broadly defined.² These are all essential to address the needs of individuals with dementia, carers and communities. However, complementary policies and further investment in prevention are required urgently to avoid the costs, both human and economic, which will accrue by 2050.

Similar barriers may apply to dementia research.³ Most research is directed towards understanding biomedical causes and developing treatments and cures. Even within this narrow focus, dementia research has gaps in several critical areas, including the role of and interactions with other conditions such as diabetes and the effects of interventions to control vascular risk factors for declining cognition.⁴ Like biomedical research, chronic disease prevention programs often operate in silos, addressing risk factors for single chronic physical diseases such as diabetes or CVD without attending to the risks these pose for other disorders, particularly those affecting the brain.⁵

The Australian Government’s 2014 Budget allocated an additional \$200 million over five years to boost [dementia research capacity](#).⁶ The National Health and Medical Research Council’s [Dementia Research Initiative](#) maintains a focus on “*strengthening coordination of Australia’s dementia research effort, implementing research findings into policy and practice and evaluating impacts.*” This focus includes dementia prevention. The evidence suggests that the impact of this investment would be strengthened if the research priorities were clearly and demonstrably aligned with a national strategic approach to dementia prevention.

The evidence summarised below makes a strong case for a new, integrated approach to risk reduction. Science is increasingly clarifying the pathways through which brain and body interactions take place and shedding light on the impacts of disease on the brain and other organs. Australia urgently needs a coordinated, integrated prevention strategy for brain and body health.

The evidence

Dementia is a public health crisis

Dementia is a group of disorders characterised by a decline from a previously attained cognitive level. Dementia may be diagnosed at any time of life and in any population, but it is more common after the age of 65. Dementia is one of the main causes of disability in later life in Australia, affecting the ability to undertake the activities of daily living with symptoms including memory loss, confusion, and problems with speech, understanding, and controlling emotions.⁷ Comorbid vascular disease is commonly observed in both older and younger people with dementia, including 80% of cases of people with Alzheimer's disease.^{8 9 10}

The growing incidence of dementia is a global public health crisis, posing significant challenges to health and social care systems worldwide. The World Health Organization (WHO) estimates that 50 million people (5% of the world's population of people over 60 years of age) are living with dementia; with this number expected to more than triple by 2050.¹¹

Dementia is feared

Research by Dementia Australia has revealed that dementia is the most feared condition after cancer.¹² A survey of over 1000 adult Australians in 2014 suggests that whilst people think that dementia is very important, many people consider it an inevitable part of ageing and do not understand the role of vascular health in dementia risk-reduction.¹³ There is an urgent need to engage with and inform the community of the association between dementia and cardiovascular risk factors, as well as the possibilities and options for prevention.^{14 15} There is increasing evidence that risks in the population can be reduced so that fewer people, at all ages, develop dementia.

Dementia in Australia: current trends

- An estimated **447,115 people have dementia**. Based on trends in population growth and ageing and the current lack of any curative interventions, the number of people with dementia will reach almost 1.1 million by 2056.¹⁶
- **The Australian Bureau of Statistics (ABS)** projects that dementia **will soon supplant heart disease as the leading cause of death in Australia**. Dementia is, currently, **the second leading cause of death**, contributing to 5.4% of all deaths in men and 10.6% of all deaths in women each year.¹⁷
- **Around 244 people per day are newly diagnosed with dementia.**¹⁸
- The number of **new cases of dementia** is estimated to increase to 318 per day by 2025 and over 650 per day
- An estimated **27,247 people have younger onset dementia**, expected to rise to 41,249 by 2058.¹⁹ This term is used to describe any form of dementia diagnosed in people under the aged of 65.²⁰
- The risk of dementia in **Indigenous Australians** is 3–5 times that of non-Indigenous persons.²¹
- People with dementia aged 65 and over have **a substantially higher average number of health conditions** than all people in this age group (5.4 and 2.9 respectively).²²

Costs of dementia

The direct and indirect costs of dementia in Australia are estimated by the National Centre of Social and Economic Modelling (NATSEM) to increase to **\$18.7 billion in today's dollars by 2025** and to **\$36.8 billion by 2056**.²³ This will place health care systems under significant additional strain. NATSEM suggests that a 5% reduction on the numbers of people over 65 with dementia could achieve immediate savings of nearly \$6 billion to 2025 and a 'staggering' \$120.4 billion by 2056.

Contributing risk factors for dementia

Biomedical and behavioural risk factors

Risk factors for dementia, as for heart disease and other chronic diseases, are classified as modifiable and non-modifiable. The scientific and policy literature documents significant associations between the modifiable risk factors for some dementias and those for other major chronic diseases, including heart disease, stroke, chronic obstructive pulmonary disease, diabetes and some cancers.²⁴ The WHO has recently reviewed the evidence on risk factors and provided [guidelines](#) for preventive interventions where the evidence is considered to be strong enough.

Physical inactivity

Physical activity has many health benefits and is a key modifiable factor involved in the development of many chronic diseases including dementia.^{25 26 27} There is evidence that the highest levels of physical activity are the most protective and may have direct beneficial effects on brain structures.^{28 29 30} Indirectly, it is suggested that the impacts of physical activity on brain health arise from the underlying impacts on cardiovascular risk factors including hypertension, insulin resistance, high cholesterol and other biological mechanisms.³¹

Smoking

Smoking is a major risk factor for a number of chronic conditions including heart disease, respiratory diseases, and many cancers. A large body of evidence highlights associations between smoking, including in mid-life, and subsequent disorders in later life including cognitive decline and dementia.^{32 33} There is good evidence for the effectiveness of smoking cessation interventions in reducing all of these health risks.^{34 35}

Nutrition

Healthy eating is an important contributor to optimal health across the life course as well as in the prevention of chronic diseases, including those that increase the risk of dementia.³⁶ Evidence suggests that diet may be involved both directly and indirectly in the development of dementia through its effect on other risk factors.³⁷ A range of high-quality studies have concluded that high levels of adherence to a Mediterranean diet, including consumption of fruit, vegetables, fish, nuts, olive oil and other unsaturated fats, whole grains and coffee may be associated with better cognitive performance and reduced incidence of dementia.^{38 39}

Alcohol

Evidence is increasing about the complex relationship between alcohol use and cognitive health and dementia. Previous reviews point to a possible beneficial effect of light to moderate alcohol use on cognitive health.⁴⁰ However, even moderate drinking has been associated with detrimental effects on brain structure, and heavy drinking is detrimentally related to dementia risk, whatever the dementia type.^{41 42 43 44 45} There is increasing evidence in support of the contention that heavy alcohol use (>12g per day) is associated with increased dementia risk.⁴⁶ Alcohol use disorders are characterised by the harmful and chronic consumption of alcohol. People who consume harmful amounts of alcohol are three times more likely to develop younger onset dementia.^{47 48 49 50} Alcohol use disorders are also associated with a range of associated risk factors for dementia, including smoking and poor nutrition and physical inactivity.⁵¹

Weight

Overweight and obesity are direct risks for a wide range of chronic diseases including Type 2 diabetes and cancer.^{52 53} They are also indirect risks for other cardiovascular risk factors including high cholesterol and hypertension.⁵⁴ There is evidence that obesity at mid-life increases the subsequent risk of dementia.⁵⁵

Diabetes

Late life diabetes has been linked to an increased risk of cognitive decline and dementia.^{56 57} In addition, secondary health problems arising from diabetes including kidney disease, eye disease, hearing impairments and CVD have all been associated with increased risk of dementia.^{58 59} There is only inconsistent evidence yet for a direct impact on cognitive outcomes from glucose-control interventions.⁶⁰ There is evidence that treating the cardiovascular comorbidities associated with diabetes may mediate risks for dementia.⁶¹

Hypertension

Hypertension in mid-life has been associated with an increased risk of dementia later.⁶² The evidence for a direct impact on blood pressure reduction in mid or later life on subsequent cognitive decline or dementia is not yet established. However, it is clear that reducing hypertension is highly beneficial in reducing cardiovascular disease and premature mortality and therefore on improving the overall health of the older population.⁶³

High cholesterol

Dyslipidaemia (high cholesterol) is an important modifiable risk factor, linked to a third of the burden of heart disease globally as well as premature mortality and disability. A number of epidemiological studies have found a link between high cholesterol and dementia, although this has not yet been demonstrated definitively.^{64 65} Other studies have identified an association between the control of cholesterol in midlife and a reduction of dementia risk.^{66 67}

A summary of these risks is provided at Appendix 2.

Potential risks

The WHO has not provided guidelines for the management of depression and mid-life hearing loss. A number of studies, including the Lancet Commission, have identified additional, modifiable risks for cognitive impairment and dementia.^{68 69}

Social risk factors

The World Health Organization guidelines do not address the influence of broader social determinants on dementia risk. Many other studies have, however, explored and described an inverse association between socioeconomic position and chronic conditions such as cardiovascular disease (CVD) and dementia.⁷⁰ The social gradient in CVD persists even after adjustment for health behaviours and clinical indicators, suggesting that other processes are involved.^{71 72}

Immune responses to chronic 'social stress' may explain some of the socioeconomic gradient in CVD and other inflammation-associated conditions, including dementia.⁷³ In support of this argument there is some evidence that social interventions, particularly higher educational attainment, may exert a protective impact. People who leave high school before year 8 have a 2.2 - fold higher risk of dementia in later life and those leaving between years 8 and 11 have 1.5 times the risk of individuals who complete high school.^{74 75 76 77 78}

There is evidence that loneliness and isolation are associated with poorer cognitive function among older adults.^{79 80} Interventions to reduce social isolation, promote social engagement and increase levels of physical activity among older people may reduce dementia risk.⁸¹

Interventions that foster social connections may be particularly beneficial for individuals with low levels of education.⁸² In addition, hearing loss may be associated with both social isolation and the incidence of dementia.^{83 84}

The *Lancet* Commission suggests that the protective effect of education and social engagement is related to variations in levels of 'cognitive reserve' (brain resilience), which is enhanced by early-life experiences, including education and intellectual stimulation.^{85 86 87} There is evidence that higher socioeconomic status during gestation and early childhood has a protective association with late-life dementia risk.^{88 89}


Cost benefits of a risk reduction approach

Up to half of the total dementia burden in Australia may be due to the effect of vascular and other modifiable risk factors.^{90 91 92} A reduction in these risk factors would lower the cost of dementia by \$24.8 billion over the next 20 years (by avoiding direct costs of \$17.6 billion and indirect costs of \$7.2 billion) and \$120.4 billion by 2056 (by avoiding direct costs of \$76.6 billion and indirect costs of \$43.8 billion).⁹³

A decline in the physical inactivity rate by 5% every five years would reduce dementia prevalence by 11% in 2051,⁹⁴ meaning 100,000 fewer Australians living with dementia by addressing just one risk factor. This effectively provides a recommended “dose” or “prescription” for effective preventive treatment that is feasible and achievable.


A much larger, cumulative reduction would be expected if more than one risk factor were reduced simultaneously, and these benefits would be enhanced by concurrent reductions in the incidence and prevalence of CVD and other chronic diseases affecting the body.^{95 96} Mounting international evidence supports these findings. Norton et al. (2009) suggested that reducing the incidence of seven risk factors (diabetes, hypertension, obesity, physical inactivity, depression, smoking and low education) by 25% would prevent three million cases of Alzheimer’s disease per decade worldwide (see Figure 2).⁹⁷

Figure 2. Potential for prevention of Alzheimer’s disease. Source: Norton et al. 2015⁹⁸



Other studies estimate that a one-year delay in the average age of onset of Alzheimer's disease due to preventive strategies could result in nearly 12 million fewer cases worldwide by 2050.⁹⁹ See Figure 3 for modelled comparisons between disease onset and progression with no risk reduction intervention and with a hypothetical risk reduction intervention from 2015.

Figure 3. Modelling data on impacts of postponing the onset and progression of Alzheimer's disease in Australia. Adapted from Access Economics 2009¹⁰⁰




Tackling alcohol abuse

There is some evidence that dementia prevention could produce even greater results if it includes action to reduce levels of heavy drinking in the Australian population.¹⁰¹ The evidence base for the impact of alcohol on brain health is not yet settled, but it is accumulating.

The need for a life-course approach

There are important life course considerations for both risk and protective factors for dementia. These diseases have a long latency period and pathology may be present for decades before cognitive symptoms are evident. The life course progression of Alzheimer's disease is described in Figure 4.

Figure 4. Life course progression of Alzheimer's disease




*MCI - mild cognitive impairment

Source: Ngandu et al. 2015

The life course nature of disease onset and progression means that there may be optimal ‘windows’ for intervention. Research increasingly indicates that the presence of risk factors in midlife, but not late life, is associated with an increased risk of dementia.¹⁰² There is international evidence that, even at age 50, cognition is affected by risk behaviours. Figure 5 identifies the optimal life course periods for preventive dementia intervention based on current knowledge. Further research, focusing on cognition in younger population cohorts, in addition to current research into diagnosed dementia in older populations, is required to improve understanding of how and when to target preventive interventions.¹⁰³

Figure 5. Optimal time window for preventive interventions. Source: Richard et al. 2012 ¹⁰⁴



Other research indicates that middle-aged people with multiple vascular risk factors such as obesity, hypertension, diabetes, high cholesterol and smoking have elevated levels of brain amyloid (the plaques and tangles in the brain associated with Alzheimer’s disease and other dementias) in later life.¹⁰⁵ These researchers recommend aligning policy and clinical practice to target cardiovascular screening and risk reduction strategies at people in middle age.

The need for a life course approach has been acknowledged by the Australian Government. In 2016 the Parliament of the Commonwealth of Australia stated that the absence of longitudinal data (and in particular longitudinal biomedical data) about people’s health as they progress from midlife into later life is an impediment to tackling chronic disease in Australia.¹⁰⁶

The strength of the evidence?

There is good evidence from Australia and internationally that preventive interventions have significant returns on investment at both individual and population levels, particularly when compared with investment in healthcare.^{107 108 109 110} There is also convincing evidence of the cost-effectiveness of interventions targeted at people at highest risk of chronic diseases.¹¹¹ As the population ages the costs of chronic diseases of the body and brain will continue to rise.¹¹² ¹¹³ The available evidence suggests that it is feasible to attempt to prevent or delay up to a third of the anticipated rise in incidence of dementia through a mix of population and individual-level interventions. Moreover, an integrated focus on better population health will reduce the prevalence of multiple chronic diseases which are, cumulatively, responsible for substantial disability and loss of independence in ageing and which are extremely costly economically, socially and individually.¹¹⁴ If the potential for prevention can be grasped, there will be significant returns on investment for the Australian taxpayer arising from increased productivity and reduced costs of health and social care.^{115 116}

In 2014, 190 leading international scientists, including several eminent Australians, wrote a letter to the *Journal of Alzheimer's Disease* making a compelling case for the preventability of dementia and calling upon the governments of the G8 countries to adopt an integrated, strategic approach to dementia prevention.¹¹⁷ These scientists were unequivocal in stating, "*there is already sufficient evidence to justify immediate action.*" The WHO and the Lancet Commission have both reinforced this position.

The evidence about dementia prevention is now sufficiently robust to be made more widely available and acted upon. The public should know what the scientific evidence demonstrates: certain healthy behaviours are known to be effective for preventing diabetes, CVD, cancer and for reducing the risk of dementia and other forms of cognitive decline.

Next steps

The Australian government has an ambitious [National Strategic Framework for Chronic Conditions](#), and has initiated a wide range of supportive programs to address risks to health in line with the goals of the Framework. These programs, in the areas of physical activity, sedentary behaviour, better ageing, alcohol harm-reduction and importantly, the development of a forthcoming national strategic action plan for reducing heart disease and stroke will all contribute to reducing risks to cognitive health.

It is appropriate to ask whether more could and should be done at policy level to grasp the full potential of these investments for brain and body health. The concern is that in the absence of a proactive effort to raise awareness of the risks to brain health and of the evidence for prevention, the challenges for health policy posed by dementia will continue to be obscured by a focus on other conditions.

The Australian Health Policy Collaboration and collaborating experts are in the process of developing an evidence based policy framework for brain health. In the interim, the evidence suggests that the following components, which are aligned with current policy approaches in Australia and are feasible and would signal serious national commitment to the prevention of dementia and cognitive decline.

1. Embedding the best evidence for dementia prevention interventions in all chronic disease policies and accompanying strategies including the forthcoming National Strategic Action Plan for Heart Disease and Stroke and the Absolute Cardio Vascular Risk Assessment Guidelines.
2. Ensuring that policies and guidelines reflect the evidence that the presence of vascular risk factors double the chances that asymptomatic, neurodegenerative pathology will lead to dementia. This requires identifying opportunities for intervention along the life course and targeting of screening and risk reduction interventions at people in their 40s and 50s who have vascular risk factors and earlier amongst Aboriginal and Torres Strait Islander groups.
3. Promoting and supporting the implementation of the WHO Guidelines on the prevention of Cognitive Decline and Dementia.
4. Integrating dementia prevention goals in the narrative and scope of relevant health improvement initiatives including physical activity and nutritional strategies and programmes, and tobacco and alcohol reduction programmes.
5. Identifying effective, cultural and gender-sensitive methods for raising public understanding of the shared risk factors for brain and body health with appropriate targeting of at-risk groups.
6. Maintaining and extending support for dementia prevention research through the NHMRC's Boosting Dementia Research initiative and enlarging the scope to address the impact of social, economic and environmental risk factors and preventative interventions.

Appendix 1. Australia's international commitments on dementia

Signatory to [the G8 Dementia Summit Declaration, 2013](#).¹¹⁸

Signatory to the first [WHO Ministerial Conference on Global Action against Dementia 2015](#).¹¹⁹

Signatory to the [WHO Global Action Plan for Prevention and Control of NCDs 2013–2020](#).¹²⁰

Signatory to [WHO Global Action Plan on the Public Health Response to Dementia 2017–2025](#).¹²¹

In 2018, the OECD reviewed progress on translating these aspirations into meaningful action amongst member nations. The OECD has concluded that '*The priority given to dementia is too low given its impact on society*'.¹²²

Appendix 2. Collaborating experts

The authors would like to thank the following people for helpful advice and contributions during the preparation of this report.

Professor Kaarin Anstey, University of New South Wales;

Professor Simon Capewell, University of Liverpool

Professor Robin Daly, Institute for Physical Activity and Nutrition, Deakin University

Professor Leon Flicker, University of Western Australia

Professor Tiina Laatikainen, National Institute for Health and Welfare of Finland and the University of Eastern Finland;

Professor Cassandra Szoeker, Healthy Ageing Program, University of Melbourne

Professor Erkki Vartiainen National Institute for Health and Welfare of Finland and the University of Eastern Finland;

In addition, the following people have generously contributed time and resources to support this work.

Ms. Toni Aslett, Stroke Foundation

Dr. Rajiv Jaysena, CSIRO

Dr. Kym Jenkins, RANZCP

Professor Sabina Knight, James Cook University

Professor Ralph Maddison, Deakin University

Professor Sharon Naismith, University of Sydney

Dr. Kristy Noble, ARACY

Professor Caryl Nowson, Deakin University

Mr. Alan Philip, Department of Health

Ms. Kaele Stokes, Dementia Australia

Dr. Sandra South, AAG

Appendix 3: WHO Guidelines: Reduction of Risk of Cognitive Decline and Dementia

Summary of key recommendations

1. Physical Inactivity

The WHO recommends that adults aged 65 years and over should do at least 150 minutes (rising to 300 minutes) of moderate intensity aerobic physical activity on at least three days each week; involving muscle strengthening and balance training. Adults of this age group whose health conditions prevent them from doing the recommended levels of activity should be as physically active as their abilities and conditions allow.

2. Smoking

The WHO recommends that interventions for tobacco cessation should be offered to all adults who use tobacco to reduce the risks of cognitive decline and dementia as well as other health benefits

3. Nutrition

The WHO recommends offering a Mediterranean -like diet to adults to with normal cognition or mild cognitive impairment to reduce the risk of cognitive decline and/or dementia

4. Alcohol

The WHO recommends that interventions that interventions aimed at ceasing or reducing harmful drinking should be offered to adults with normal cognition or mild cognitive impairment to reduce the risk of cognitive decline and/or dementia as well as other health benefits

5. Weight Management

The WHO recommends that interventions for mid-life overweight and/or obesity be offered to reduce the risk of cognitive decline and dementia but emphasises that lifestyle interventions that include dietary changes and increased physical activity have the best results

6. Diabetes Management

The WHO recommends that management of diabetes in the form of medications and/or lifestyle interventions should be offered to adults with diabetes to reduce the risk of cognitive decline and/or dementia.

7. Hypertension Management

The WHO recommends that hypertension reduction interventions be offered to adults with hypertension to reduce the risk of cognitive decline and/or dementia.

8. Dyslipidaemia Management

The WHO recommends that management of dyslipidaemia at mid-life should be offered to reduce the risk of cognitive decline and dementia.

Source: World Health Organization 2019, Risk Reduction of Cognitive Decline and Dementia: *WHO Guidelines*.

https://www.who.int/mental_health/neurology/dementia/guidelines_risk_reduction/en/

References

- ¹ Finnish Ministry of Social Affairs and Health 2013, *National Memory Programme 2012–2020: Creating a “memory-friendly” Finland*, <http://julkaisut.valtioneuvosto.fi/handle/10024/74501>.
- ² UK Health Forum 2014, *Promoting brain health: Developing a prevention agenda linking dementia and other non-communicable diseases*, UK Health Forum, London.
- ³ UK Health Forum 2014, *Promoting brain health: Developing a prevention agenda linking dementia and other non-communicable diseases*, UK Health Forum, London.
- ⁴ Snyder, HM, Corriveau, RA, Craft, S, Faber, JE, Greenberg, SM, Knopman, D, Lamb, BT, Montine, TJ, Nedergaard, M, Schaffer, CB & Schneider, JA 2015, Vascular contributions to cognitive impairment and dementia including Alzheimer's disease, *Alzheimer's & Dementia*, vol. 11, no. 6, pp. 710-717.
- ⁵ Duggan, M 2015, *Beyond the fragments: preventing the costs and consequences of chronic physical and mental diseases*, Australian Health Policy Collaboration Issues paper No. 2015-05, Australian Health Policy Collaboration, Melbourne.
- ⁶ Department of Health 2017, *Portfolio Budget Statements (2017-18) Budget Related Paper No. 1.10 Health Portfolio*, [https://www.health.gov.au/internet/budget/publishing.nsf/Content/2017-2018_Health_PBS_sup4/\\$File/2017-18_Health_PBS_Complete.pdf](https://www.health.gov.au/internet/budget/publishing.nsf/Content/2017-2018_Health_PBS_sup4/$File/2017-18_Health_PBS_Complete.pdf), p. 390.
- ⁷ Australian Institute of Health and Welfare 2012, *Dementia in Australia*, <http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737422943>
- ⁸ Hachinski, V 2015, Stroke and potentially preventable dementias proclamation, *Stroke*, pp. 3039–3040, <http://stroke.ahajournals.org/content/46/11/3039>.
- ⁹ Kling, MA, Trojanowski, JQ, Wolk, DA, Lee, VM & Arnold, SE 2013, Vascular disease and dementias: paradigm shifts to drive research in new directions, *Alzheimer's & Dementia*, vol. 9, no. 1, pp. 76–92.
- ¹⁰ Toledo, JB, Arnold, SE, Raible, K, Brettschneider, J, Xie, SX, Grossman, M, Monsell, SE, Kukull, WA & Trojanowski, JQ 2013, Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain*, vol. 136, no. 9, pp. 2697-2706.
- ¹¹ World Health Organization 2019, Risk Reduction of Cognitive Decline and Dementia: *WHO Guidelines*. https://www.who.int/mental_health/neurology/dementia/guidelines_risk_reduction/en/
- ¹² Phillipson, L, Magee, C, Jones, S & Skladzie, E 2012, *Exploring dementia and stigma beliefs: a pilot study of Australian adults aged 40 to 65*, Paper 28, Alzheimer's Australia, https://www.fightdementia.org.au/files/20120712_US_28_Stigma_Report.pdf
- ¹³ Smith, B.J., Ali, S. and Quach, H., 2014. Public knowledge and beliefs about dementia risk reduction: a national survey of Australians. *BMC Public Health*, 14(1), p.661.
- ¹⁴ Schomerus, G, Schwahn, C, Holzinger, A, Corrigan, PW, Grabe, HJ, Carta, MG & Angermeyer, MC 2012, Evolution of public attitudes about mental illness: a systematic review and meta-analysis, *Acta Psychiatrica Scandinavica*, vol. 12, iss. 5, no. 6, pp. 440–452.
- ¹⁵ Hachinski, V 2015, Stroke and potentially preventable dementias proclamation, *Stroke*, vol. 46, pp. 3039–3040, <http://stroke.ahajournals.org/content/46/11/3039>
- ¹⁶ Dementia Australia 2018, *Dementia Prevalence Data 2018-2058*, commissioned research undertaken by NATSEM, University of Canberra
- ¹⁷ Australian Bureau of Statistics 2015, *Causes of Death, Australia, 2015*, cat. no. 3303.0, ABS, Canberra.
- ¹⁸ Australian Bureau of Statistics 2015, *Causes of Death, Australia, 2015*, cat. no. 3303.0, ABS, Canberra.
- ¹⁹ *Dementia Australia (2018). Dementia Prevalence Data 2018-2058, commissioned research undertaken by NATSEM, University of Canberra.* <https://www.dementia.org.au/information/statistics/prevalence-data>.
- ²⁰ Australian Bureau of Statistics 2015, *Causes of Death, Australia, 2015*, cat. no. 3303.0, ABS, Canberra.
- ²¹ ABS 2013, *Census of Population and Housing: Socio-economic Indexes for Areas (SEIFA), Australia, 2011*, cat. 2033.0.55.001, ABS, Canberra.
- ²² Australian Institute of Health and Welfare 2012, *Dementia in Australia*, cat. no. AGE 70, AIHW, Canberra.
- ²³ The National Centre for Social and Economic Modelling 2016, *Economic cost of dementia in Australia 2016-2056*, <https://www.fightdementia.org.au/files/NATIONAL/documents/The-economic-cost-of-dementia-in-Australia-2016-to-2056.pdf>
- ²⁴ World Health Organization and Alzheimer's International 2012, *Dementia. A public health priority*, http://www.who.int/mental_health/publications/dementia_report_2012/en/

- ²⁵ Lee, IM, Shiroma, EJ, Lobelo, F, Puska, P, Blair, SN, Katzmarzyk, PT and Lancet Physical Activity Series Working Group 2012, Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy, *The Lancet*, vol. 380, no. 9838, pp. 219-229.
- ²⁶ Gallaway, P., Miyake, H., Buchowski, M., Shimada, M., Yoshitake, Y., Kim, A. and Hongu, N., 2017. Physical activity: a viable way to reduce the risks of mild cognitive impairment, Alzheimer's disease, and vascular dementia in older adults. *Brain sciences*, 7(2), p.22.
- ²⁷ Hamer, M. and Chida, Y., 2009. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychological medicine*, 39(1), pp.3-11.
- ²⁸ Hamer, M. and Chida, Y., 2009. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychological medicine*, 39(1), pp.3-11.
- ²⁹ Sofi, F., Valecchi, D., Bacci, D., Abbate, R., Gensini, G.F., Casini, A. and Macchi, C., 2011. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. *Journal of internal medicine*, 269(1), pp.107-117.
- ³⁰ Rovio, S., Spulber, G., Nieminen, L.J., Niskanen, E., Winblad, B., Tuomilehto, J., Nissinen, A., Soininen, H. and Kivipelto, M., 2010. The effect of midlife physical activity on structural brain changes in the elderly. *Neurobiology of aging*, 31(11), pp.1927-1936.
- ³¹ World Health Organization, WHO Global recommendations on physical activity for health. Geneva: World Health Organization; 2011.
- ³² Beydoun, M.A., Beydoun, H.A., Gamaldo, A.A., Teel, A., Zonderman, A.B. and Wang, Y., 2014. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. *BMC public health*, 14(1), p.643.
- ³³ Di Marco, L.Y., Marzo, A., Muñoz-Ruiz, M., Ikram, M.A., Kivipelto, M., Ruefenacht, D., Venneri, A., Soininen, H., Wanke, I., Ventikos, Y.A. and Frangi, A.F., 2014. Modifiable lifestyle factors in dementia: a systematic review of longitudinal observational cohort studies. *Journal of Alzheimer's disease*, 42(1), pp.119-135.
- ³⁴ Pirie, K., Peto, R., Reeves, G.K., Green, J., Beral, V. and Million Women Study Collaborators, 2013. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. *The Lancet*, 381(9861), pp.133-141.
- ³⁵ Taylor, G., McNeill, A., Girling, A., Farley, A., Lindson-Hawley, N. and Aveyard, P., 2014. Change in mental health after smoking cessation: systematic review and meta-analysis. *Bmj*, 348, p.g1151.
- ³⁶ Tuomilehto, J., Lindström, J., Eriksson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M. and Salminen, V., 2001. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New England Journal of Medicine*, 344(18), pp.1343-1350.
- ³⁷ Swaminathan, A. and Jicha, G.A., 2014. Nutrition and prevention of Alzheimer's dementia. *Frontiers in aging neuroscience*, 6, p.282.
- ³⁸ Singh, B., Parsaik, A.K., Mielke, M.M., Erwin, P.J., Knopman, D.S., Petersen, R.C. and Roberts, R.O., 2014. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. *Journal of Alzheimer's disease*, 39(2), pp.271-282.
- ³⁹ Wu, L. and Sun, D., 2017. Adherence to Mediterranean diet and risk of developing cognitive disorders: An updated systematic review and meta-analysis of prospective cohort studies. *Scientific reports*, 7, p.41317.
- ⁴⁰ Britton, A, Singh-Manoux, A & Marmot, M 2004, Alcohol consumption and cognitive function in the Whitehall II Study, *American Journal of Epidemiology*, vol. 160, no. 3, pp. 240-7.
- ⁴¹ Schwarzingler, M, Pollock, B, Hasan, O, Dufouil, C, Rehm, J for the QalyDays Study Group 2018, Contribution of alcohol use disorders to the burden of dementia in France 2008-13: a nationwide retrospective cohort study, *Lancet Public Health*, vol. 3, no. 3, pp. e124-e132, doi:10.1016/S2468-2667(18)30022/7.
- ⁴² Ballard, C & Lang I 2018, Alcohol and dementia: a complex relationship with potential for dementia prevention, *Lancet Public Health*, vol. 3, no. 3, pp. e103-e104, doi:10.1016/S2468-2667(18)30031-8.
- ⁴³ Verbaten, MN 2009, Chronic effects of low to moderate alcohol consumption on structural and functional properties of the brain: beneficial or not? *Human Psychopharmacology: Clinical and Experimental*, vol. 24, no. 3, pp. 199-205.
- ⁴⁴ Topiwala, A, Allan, CL, Valkanova, V, Zsoldos, E, Filippini, N, Sexton, C, Mahmood, A, Fooks, P, Singh-Manoux, A, Mackay, CE, Kivimäki, PM & Ebmeier KP 2017, Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study, *British Medical Journal*, vol. 357, p. j2353.
- ⁴⁵ Gupta, S & Warner J 2008, Alcohol-related dementia: a 21st-century silent epidemic? *British Journal of Psychiatry*, vol. 193, pp. 351-53.
- ⁴⁶ Kadlecová, P, Andel, R, Mikulík, R, Handing, EP and Pedersen, NL, 2015, Alcohol consumption at midlife and risk of stroke during 43 years of follow-up: cohort and twin analyses, *Stroke*, vol. 46, no. 3, pp. 627-633.

- ⁴⁷ Schwarzingger, M, Pollock, BG, Hasan, OS, Dufouil, C, Rehm, J, Baillot, S, Guibert, Q, Planchet, F and Luchini, S 2018, Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study, *The Lancet Public Health*, vol. 3, no. 3, pp.e124-e132.
- ⁴⁸ Oslin, D, Atkinson, RM, Smith, DM & Hendrie, H 1998, Alcohol related dementia: proposed clinical criteria, *International Journal of Geriatric Psychiatry*, vol. 13, pp. 203–12.
- ⁴⁹ Ridley, NJ, Draper, B & Withall, A 2013, Alcohol-related dementia: an update of the evidence, *Alzheimer's Research & Therapy*, vol. 5, p. 3.
- ⁵⁰ Nordstrom, P, Nordstrom, A, Eriksson, M, Wahlund, LO & Gustafson, Y 2013, Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study, *JAMA Internal Medicine*, vol. 173, pp. 1612-18.
- ⁵¹ Ott, A, Slioter, AJC, Hofman, A, van Harskamp, F, Witteman, JCM, Van Broeckhoven, C, Van Duijn, CM and Breteler, MMB 1998, Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. *The Lancet*, vol. 351, no. 9119, pp. 1840-1843.
- ⁵² WHO (2019b) Global Health Observatory data: Obesity.
https://www.who.int/gho/ncd/risk_factors/overweight_obesity/obesity_adults/en/ Accessed 29th May 2019
- ⁵³ Renehan, A.G., Zwahlen, M. and Egger, M., 2015. Adiposity and cancer risk: new mechanistic insights from epidemiology. *Nature Reviews Cancer*, 15(8), p.484.
- ⁵⁴ Fontana, L. and Hu, F.B., 2014. Optimal body weight for health and longevity: bridging basic, clinical, and population research. *Aging cell*, 13(3), pp.391-400.
- ⁵⁵ Albanese, E., Davis, B., Jonsson, P.V., Chang, M., Aspelund, T., Garcia, M., Harris, T., Gudnason, V. and Launer, L.J., 2015. Overweight and obesity in midlife and brain structure and dementia 26 years later: the AGES-Reykjavik Study. *American journal of epidemiology*, 181(9), pp.672-679.
- ⁵⁶ Luchsinger, J.A., 2010. Diabetes, related conditions, and dementia. *Journal of the neurological sciences*, 299(1-2), pp.35-38.
- ⁵⁷ Prince, M., Albanese, E., Guerchet, M. and Prina, M., 2014. Dementia and risk reduction: an analysis of protective and modifiable factors. *World Alzheimer Report*, pp.66-83.
- ⁵⁸ Bruce, D.G., Davis, W.A., Starkstein, S.E. and Davis, T.M., 2014. Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: the Fremantle Diabetes Study. *Journal of Alzheimer's Disease*, 42(s3), pp.S63-S70.
- ⁵⁹ Exalto, L.G., Biessels, G.J., Karter, A.J., Huang, E.S., Katon, W.J., Minkoff, J.R. and Whitmer, R.A., 2013. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. *The Lancet Diabetes & Endocrinology*, 1(3), pp.183-190.
- ⁶⁰ Launer, L.J., Miller, M.E., Williamson, J.D., Lazar, R.M., Gerstein, H.C., Murray, A.M., Sullivan, M., Horowitz, K.R., Ding, J., Marcovina, S. and Lovato, L.C., 2011. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *The Lancet Neurology*, 10(11), pp.969-977.
- ⁶¹ Johnson, M.L., Parikh, N., Kunik, M.E., Schulz, P.E., Patel, J.G., Chen, H., Aparasu, R.R. and Morgan, R.O., 2012. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. *Alzheimer's & Dementia*, 8(5), pp.437-444.
- ⁶² Kivipelto, M., Helkala, E.L., Laakso, M.P., Hanninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannerman, A., Tuomilehto, J., Nissinen, A. and Soininen, H., 2002. Apolipoprotein E ϵ 4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. *Annals of internal medicine*, 137(3), pp.149-155.
- ⁶³ Musini, V.M., Tejani, A.M., Bassett, K. and Wright, J.M., 2009. Pharmacotherapy for hypertension in the elderly. *Cochrane Database of Systematic Reviews*, (4).
- ⁶⁴ Richardson WS, Glasziou P, Polashenski WA, Wilson MC (2000). A new arrival: evidence about differential diagnosis. *Evidence Based Medicine*. 5(6):164.
- ⁶⁵ Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K et al. (2001). Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *BMJ*. 322(7300):1447–1451.
- ⁶⁶ Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ (2017). Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. *Alzheimer's Research & Therapy*. 9(10):1.
doi:10.1186/s13195-017-0237-y
- ⁶⁷ Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, Krewski D (2017). Risk factors associated with the onset and progression of Alzheimer's disease: a systematic review of the evidence. *Neurotoxicology*. 61:143–187.
doi:10.1016/j.neuro.2017.03.00
- ⁶⁸ Norton, S, Matthews, FE, Barnes, DE, Yaffe, K & Brayne, C 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, *The Lancet Neurology*, vol. 13, no. 8, pp. 788-794.

-
- ⁶⁹ Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S.G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J. and Cooper, C., 2017. Dementia prevention, intervention, and care. *The Lancet*, 390(10113), pp.2673-2734.
- ⁷⁰ McMunn, A, Nazroo, J & Breeze, E 2009, Inequalities in health at older ages: a longitudinal investigation of the onset of illness and survival effects in England, *Age and Ageing*, vol. 38, no. 2, pp. 181–187.
- ⁷¹ Lin, J, Epel, E & Blackburn, E 2012, Telomeres and lifestyle factors: roles in cellular aging, *Mutation Research*, vol. 730, no. 1, pp. 85–89.
- ⁷² Lantz, PM, House, JS, Lepkowski, JM, Williams, DR, Mero, RP & Chen, J 1998, Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults, *JAMA*, vol. 279, no. 21, pp. 1703–1708.
- ⁷³ Lin, J, Epel, E & Blackburn, E 2012, Telomeres and lifestyle factors: roles in cellular aging, *Mutation Research*, vol. 730, no. 1, pp. 85–89.
- ⁷⁴ Beydoun, MA, Beydoun, HA, Gamaldo, AA, Teel, A, Zonderman, AB & Wang Y 2014, Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis, *BMC Public Health*, vol. 14, no.1, p. 643.
- ⁷⁵ Caamaño-Isorna, F, Corral, M, Montes-Martínez, A & Takkouche, B 2006, Education and dementia: a meta-analytic study, *Neuroepidemiology*, vol. 26, no. 4, pp. 226–232.
- ⁷⁶ Anstey, KJ, Cherbuin, N & Herath, PM 2013, Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention, *Prevention Science*, vol. 14, no. 4, pp. 411–421.
- ⁷⁷ Baumgart, M, Snyder, HM, Carrillo, MC, Fazio, S, Kim, H and Johns, H, 2015 Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective, *Alzheimer's & Dementia*, vol. 11, no. 6, pp. 718-726.
- ⁷⁸ Kivipelto, M, Ngandu, T, Laatikainen, T, Winblad, B, Soininen, H & Tuomilehto, J 2006, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study, *Lancet Neurol.* vol. 5, pp. 735–41
- ⁷⁹ Holwerda, TJ, Deeg, DJ, Beekman, AT, van Tilburg, TG, Stek, ML, Jonker, C & Schoevers, RA 2012, Feelings of loneliness, but not social isolation, predict dementia onset: results from the Amsterdam Study of the Elderly (AMSTEL), *J Neurol Neurosurg Psychiatry*, p. jnnp-2012.
- ⁸⁰ Shankar, A, Hamer, M, McMunn, A & Steptoe, A 2013, Social isolation and loneliness: relationships with cognitive function during 4 years of follow-up in the English Longitudinal Study of Ageing, *Psychosomatic Medicine*, vol. 75, no. 2, pp. 161-170.
- ⁸¹ Karp, A, Paillard-Borg, S, Wang, HX, Silverstein, M, Winblad, B & Fratiglioni, L 2006, Mental, physical and social components in leisure activities equally contribute to decrease dementia risk, *Dementia and Geriatric Cognitive Disorders*, vol. 21, no. 2, pp. 65–73.
- ⁸² Kuiper, JS, Zuidersma, M, Voshaar, RCO, Zuidema, SU, van den Heuvel, ER, Stolk, RP & Smidt, N 2015, Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies, *Ageing Research Reviews*, vol. 22, pp. -57.
- ⁸³ Lin, FR, Metter, EJ, O'Brien, RJ, Resnick, SM, Zonderman, AB & Ferrucci, L 2011, Hearing loss and incident dementia, *Archives of Neurology*, vol. 68, no. 2, pp. 214-220.
- ⁸⁴ Lin, FR, Ferrucci, L, Metter, EJ, An, Y, Zonderman, AB & Resnick, SM 2011, Hearing loss and cognition in the Baltimore Longitudinal Study of Aging, *Neuropsychology*, vol. 25, no. 6, p. 763.
- ⁸⁵ Livingston, G, Sommerlad, A, Orgeta, V, Costafreda, SG, Huntley, J, Ames, D, Ballard, C, Banerjee, S, Burns, A, Cohen-Mansfield, J & Cooper, C 2017, Dementia prevention, intervention, and care, *The Lancet*, vol. 390, no. 10113, pp. 2673-2734.
- ⁸⁶ Stern, Y 2005, Lifestyle and other risk factors: *Cognitive reserve*. *Alzheimer's & Dementia*, vol. 1, iss. 1, p. S93.
- ⁸⁷ Prince, M, Acosta, D, Ferri, CP, Guerra, M, Huang, Y, Rodriguez, JLL, Salas, A, Sosa, AL, Williams, JD, Dewey, ME & Acosta, I 2012, Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study, *The Lancet*, vol. 380, no. 9836, pp. 50-58.
- ⁸⁸ Borenstein, A & Mortimer, J 2016, *Alzheimer's disease: life course perspectives on risk reduction* (1st ed.), Academic Press, Cambridge MA.
- ⁸⁹ Larson, EB 2010, Prospects for delaying the rising tide of worldwide, late-life dementias, *International Psychogeriatrics*, vol. 22, pp. 1196-1202.
- ⁹⁰ Australian Institute of Health and Welfare 2016, *Contribution of vascular diseases and risk factors to the burden of dementia in Australia: Australian Burden of Disease Study 2011*, Australian Burden of Disease Study

series no. 9, cat. no. BOD 10, AIHW, Canberra,

<http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129557756>

⁹¹ Farrow, M & O'Connor, E 2012, *Targeting brain, body and heart for cognitive health and dementia prevention, current evidence and future directions*, Paper 29, Alzheimer's Australia,

https://www.fightdementia.org.au/sites/default/files/YBM_evidence_paper_29_lores.pdf

⁹² Ashby-Mitchell, K, Burns, R, Shaw, J and Anstey, KJ 2017, Proportion of dementia in Australia explained by common modifiable risk factors, *Alzheimer's Research & Therapy*, vol. 9, no. 1, p. 11.

⁹³ The National Centre for Social and Economic Modelling 2016, *Economic cost of dementia in Australia 2016-2056*, NATSEM, Canberra, <https://www.fightdementia.org.au/files/NATIONAL/documents/The-economic-cost-of-dementia-in-Australia-2016-to-2056.pdf>

⁹⁴ Nepal, B, Brown, L & Ranmuthugala, G 2010, Modelling the impact of modifying lifestyle risk factors on dementia prevalence in Australian population aged 45 years and over, 2006-2051, *Australasian Journal on Ageing*, vol. 29, no. 3, pp. 111–116.

⁹⁵ Access Economics 2009, *Keeping dementia front of mind: incidence and prevalence 2009–2050*, Alzheimer's Australia, http://www.alzheimers.org.au/common/files/NAT/20090800_Nat_AE_FullKeepDemFrontMind.pdf

⁹⁶ Gorelick, PB, Scuteri, A, Black, SE, DeCarli, C, Greenberg, SM, Iadecola, C, Launer, LJ, Laurent, S, Lopez, OL, Nyenhuis, D & Petersen, RC 2011, Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association, *Stroke*, vol. 42, no. 9, pp. 2672-2713.

⁹⁷ Norton, S, Matthews, FE, Barnes, DE, Yaffe, K & Brayne, C 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, *The Lancet Neurology*, vol. 13, no. 8, pp. 788-794.

⁹⁸ Norton, S, Matthews, FE, Barnes, DE, Yaffe, K & Brayne, C 2014, Potential for primary prevention of Alzheimer's disease: an analysis of population-based data, *The Lancet Neurology*, vol. 13, no. 8, pp. 788-794.

⁹⁹ Brookmeyer, R, Johnson, E, Ziegler-Graham, K & Arrighi, HM 2007, Forecasting the global burden of Alzheimer's disease, *Alzheimer's & Dementia*, vol. 3, no. 3, pp. 186–191.

¹⁰⁰ Access Economics 2009, *Keeping dementia front of mind: incidence and prevalence 2009–2050*, Alzheimer's Australia, http://www.alzheimers.org.au/common/files/NAT/20090800_Nat_AE_FullKeepDemFrontMind.pdf

¹⁰¹ Schwarzingler, M., Pollock, B.G., Hasan, O.S., Dufouil, C., Rehm, J., Baillot, S., Guibert, Q., Planchet, F. and Luchini, S., 2018. Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study. *The Lancet Public Health*, 3(3), pp.e124-e132.

¹⁰² Abell, JG, Kivimäki, M, Dugravot, A, Tabak, AG, Fayosse, A, Shipley, M, Sabia, S and Singh-Manoux, A 2018, Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension, *European Heart Journal*, vol. 39, no. 33, pp. 3119-3125.

¹⁰³ Villemagne, VL, Burnham, S, Bourgeat, P, Brown, B, Ellis, KA, Salvado, O, Szoek, C, Macaulay, SL, Martins, R, Maruff, P and Ames, D 2013, Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, *The Lancet Neurology*, vol. 12, no. 4, pp. 357-367.

¹⁰⁴ Richard, E, Andrieu, S, Solomon, A, Mangialasche, F, Ahtiluoto, S, Moll van Charante, EP, Coley, N, Fratiglioni, L, Neely, AS, Vellas, B, van Gool, WA & Kivipelto, M 2012, Methodological challenges in designing dementia prevention trials – the European Dementia Prevention Initiative (EDPI), *Journal of the Neurological Sciences*, vol. 322, no. 1, pp. 64–70.

¹⁰⁵ Gottesman, R, Schneider, A, Zhou, Y, Coresh, J, Green, E, Gupta, N, Knopman, DS, Mintz, A, Rahmim, A, Sharrett, AR, Wagenknecht, LE, Wong, DF & Mosley, TH 2017, Association between midlife vascular risk factors and estimated brain amyloid deposition, *JAMA*, vol. 317, no. 14, pp. 1443-1450, doi:10.1001/jama.2017.3090.

¹⁰⁶ House of Representatives Standing Committee on Health 2016, *Inquiry into Chronic Disease Prevention and Management in Primary Health Care*, Submission 143, p. 32, Dept of Health ed. Canberra, Australia: The Parliament of the Commonwealth of Australia

¹⁰⁷ Barton, P, Andronis, L, Briggs, A, McPherson, K & Capewell, S 2011, Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study, *BMJ*, vol. 343, p. d4044.

¹⁰⁸ Jørgensen, T, Capewell, S, Prescott, E, Allender, S, Sans, S, Zdrojewski, T, De Bacquer, D, De Sutter, J, Franco, OH, Løgstrop, S & Volpe, M 2013, Population-level changes to promote cardiovascular health, *European Journal of Preventive Cardiology*, vol. 20, no. 3, pp. 409-421.

¹⁰⁹ Owen, L, Morgan, A, Fischer, A, Ellis, S, Hoy, A & Kelly, MP 2012, The cost-effectiveness of public health interventions, *Journal of Public Health*, vol. 34, iss. 1, pp. 37–45, <https://doi.org/10.1093/pubmed/fdr075>

¹¹⁰ Masters, R, Anwar, E, Collins, B, Cookson, R & Capewell, S 2017, Return on investment of public health interventions: a systematic review, *Journal of Epidemiology and Community Health*, vol. 71, no. 8, pp. 827-834.

-
- ¹¹¹ Lim, SS, Gaziano, TA, Gakidou, E, Reddy, KS, Farzadfar, F, Lozano, R & Rodgers, A 2007, Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs, *The Lancet*, vol. 370, no. 9604, pp. 2054-2062.
- ¹¹² Willcox, S 2014, *Chronic diseases in Australia: the case for changing course*, Australian Health Policy Collaboration Issues paper no. 2014-02, AHPC, Melbourne, <https://www.vu.edu.au/sites/default/files/AHPC/pdfs/Chronic-diseases-in-Australia-the-case-for-changing-course-sharon-willcox.pdf>
- ¹¹³ Commonwealth of Australia 2016, *Inquiry into Chronic Disease Prevention and Management in Primary Health Care*, House of Representatives Standing Committee on Health, https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health/Chronic_Disease/Report
- ¹¹⁴ Mangialasche, F, Kivipelto, M, Solomon, A & Fratiglioni, L 2012, Dementia prevention: current epidemiological evidence and future perspective, *Alzheimer's Research & Therapy*, vol. 4, no. 1, p. 6.
- ¹¹⁵ Wimo, A, Jönsson, L, Bond, J, Prince, M & Winblad, B 2013, The worldwide economic impact of dementia 2010, *Alzheimer's & Dementia*, vol. 9, no. 1, pp. 1-11.
- ¹¹⁶ The National Centre for Social and Economic Modelling 2016, *Economic cost of dementia in Australia 2016-2056*, NATSEM, Canberra, <https://www.fightdementia.org.au/files/NATIONAL/documents/The-economic-cost-of-dementia-in-Australia-2016-to-2056.pdf>
- ¹¹⁷ Smith, AD & Yaffe, K 2014, Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts, *Journal of Alzheimer's Disease*, vol. 38, pp. 699-703.
- ¹¹⁸ G8 Health and Science Ministers 2013, *G8 Dementia Summit Declaration*, <http://www.g8.utoronto.ca/healthG8/g8-dementia-summit-declaration-2013.pdf>
- ¹¹⁹ World Health Organization 2015, *First WHO ministerial conference on global action against dementia: meeting report*, WHO Headquarters, Geneva, 16-17 March, http://apps.who.int/iris/bitstream/10665/179537/1/9789241509114_eng.pdf
- ¹²⁰ World Health Organization 2015, *Global action plan for the prevention and control of NCDs 2013-2020*, WHO, Geneva, http://www.who.int/nmh/events/ncd_action_plan/en/
- ¹²¹ World Health Organization 2016, *Global Action Plan on the Public Health Response to Dementia 2017-2025*, WHO, Geneva, http://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/
- ¹²² OECD 2018 Policy Brief. Renewing Priority for Dementia: Where do we stand? <http://www.oecd.org/health/health-systems/Renewing-priority-for-dementia-Where-do-we-stand-2018.pdf>



Mitchell Institute at Victoria University
300 Queen Street, Melbourne, Victoria 3000
+61 3 9919 1820
info@mitchellinstitute.org.au
mitchellinstitute.org.au